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Tuscany
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Marina Di Pirro1,2, Maria Grazia Giovannini2, Maria Teresa Cariglia2, Luigi Gori5,
Fabio Firenzuoli5 and Alessandro Mugelli1,2
1Tuscan Regional Centre of Pharmacovigilance, 2Department of Preclinical and Clinical Pharmacology, Florence,
3Department of Statistical Science, University of Florence, 4Department of Emergency Medicine, ASL 4 Hospital,
Prato and 5Centre of Natural Medicine, ASL 11 Hospital, Empoli, Italy
To explore pregnant women’s use, attitudes, knowledge and beliefs of complementary and
alternative drugs (CADs) defined as products manufactured from herbs or with a natural
origin. A preliminary survey was conducted among 172 pregnant women in their third trimester
of pregnancy, consecutively recruited in two obstetrical settings; 15 women were randomly
selected to compute a test-to-retest analysis. Response rate was 87.2%. Test-to-retest analysis
showed a questionnaire’s reproducibility exceeding a K-value of 0.7 for all items. Mean age was
32.4 0.4 years; most women were nulliparae (62.7%). The majority of subjects (68%) declared
to have used one or more CADs during their lifetime; 48% of pregnant women reported taking
at least one CAD previously and during the current pregnancy. Women’s habitual use of CADs
meant they were at higher risk of taking CADs also during pregnancy (adjusted odds
ratio=10.8; 95% confidence interval: 4.7–25.0). Moreover, 59.1% of the subjects were unable
to correctly identify the type of CADs they were using. The majority of women resorted to
gynecologists as the primary information source for CADs during pregnancy, while they mainly
referred to herbalists when not pregnant. Habitual use of CADs seems to be a strong predictor
for their ingestion also during pregnancy; in addition most subjects were unable to correctly
identify the products they were taking. In the light of the scanty data concerning the safety of
CADs during pregnancy, these preliminary results confirm the need to investigate thoroughly
the situation of pregnant women and CADs consumption.
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Introduction
According to the definition provided by the National
Center for Complementary and Alternative Medicine
(NCCAM), ‘Complementary and Alternative Medicine
(CAM) is a broad domain of healing resources that
encompasses all health systems, modalities and practices
and their accompanying theories and beliefs, other than
those intrinsic to the politically dominant health system
of a particular society or culture in a given historical
period. CAM includes all such practices and ideas self-
defined by their users as preventing or treating illness or
promoting health and well-being’ (1).
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In 1996, the British Medical Journal, published the news
‘Complementary medicine is booming worldwide’ (2,3).
Consistently in the last decade, an important increase in
the use of CAM has been observed in Europe, USA and
Australia (2,4,5), in which most studies showed women as
the major users of alternative medicines when compared
with men (2,4,5). In Italy, during the period 1997–99,
almost 9 million people used at least one non-conven-
tional therapy, where homeopathy was the most com-
monly used (8.2% of the population). The main reason
for use was concern about the toxicity of conventional
medicines (6).
Similarly, the attitude of pregnant women towards
CAM, particularly with regard to complementary and
alternative drugs (CADs), including homeopathy, herbal
drugs and other products of natural origin, seems to be an
appealing approach to guarantee the well-being of their
unborn children. Nevertheless, CADs are not always
subject to the same regulations as conventional medicines
and there is often little concerning purity, safety or
teratogenicity of this kind of medications. These aspects
were discussed in 1996 by a Canadian pregnancy informa-
tion centre, the Mother-Risk Centre (7) as well as by the
most recent medical literature (8–14). Some remedies such
as Valerian (Valeriana officinalis), Bearberry (Arctosta-
phylos uva-ursi) and Gingko (Gingko biloba) can be
contraindicated in pregnancy in the light of little or
absent data on their safety profile (8–14). In fact, only few
studies have investigated the effect of herbal drugs on
human pregnancy outcome (15,16).
In Italy specific surveys that investigate the attitude of
pregnant woman towards CADs are still lacking. The
only available information on this issue, focused on
herbal medications, has been reported in a survey
performed by Zaffani et al. (17): 35.23% of the sample
admitted to use herbal drugs during pregnancy or to treat
their children’s diseases.
Additionally, because of the well-known CADs hetero-
geneity, patients might have difficulty in recognizing or
identifying the product they are using. This issue is
widely debated both in Italy and in other western
countries but, to our knowledge, an epidemiological
evaluation of this topic is still absent.
Thus, the purpose of this preliminary study was to
explore the attitudes, beliefs, knowledge of CADs in a
sample of pregnant Italian women.
Methods
Study Population
This preliminary survey was conducted over a 2-month
period (twice a week, from June 1 to July 31, 2006) in
two gynecology wards of two general hospitals located
in Florence (Tuscany, Italy), after institutional
authorization was received. The sample population
consisted of women in the last trimester of pregnancy,
not randomly selected, attending the outpatient depart-
ment or admitted as inpatients to delivery.
All potential participants, consecutively recruited,
received written and oral information about the study
and written informed consent was obtained.
Data Collection
Data were collected by means of a semi-structured
(Appendix 1) questionnaire administered by a trained
midwife using a face-to-face interview of 20min. Before
each interview women received a definition of CADs,
generally defined as any type of product manufactured
from plants or with natural origin.
The questionnaire was composed of 20 items, close and
open-ended questions, divided into three sections. The
first section comprised the patient’s demographic data,
the eventual presence of chronic diseases and use of
CADs outside or in previous pregnancies. The second
section investigated the use of CADs during the current
pregnancy and the timing of administration (I, II, III
trimester). The trained interviewer was instructed to get
as much information as possible on CADs ingested by
pregnant women. Women in the study were also asked to
classify products in the following categories: homeopathic
drugs, Bach flowers, herbal drugs, herbal preparations
and natural products. Afterwards each product was
correctly classified by a trained specialist by means of
the European Pharmacopeia (18).
Finally, the third and last section investigated infor-
mation sources on CADs: women were asked, through
close-ended questions, what was their usual source of
information about CADs (the choices were: pharmacist,
herbalist, midwife, general practitioner, internet, friends/
family, magazines); two close-ended questions finally
investigated the beliefs of pregnant women about the
safety and efficacy of CADs.
The questionnaire was designed and planned according
to the most recent methodological literature (19–23).
It was validated by an ad hoc panel of experts (phar-
macologists, epidemiologists, toxicologists, pharmacists
and clinicians) of the Tuscan Regional Centre of
Pharmacovigilance, a clinician of the regional referring
Centre of Natural Medicine and a group of gynecologists
and midwives of both hospital settings. At first a focus
group of six volunteers, as a small target population,
participated in a systematic discussion, concerning ques-
tionnaire structure, guided by a moderator. In this way
we evaluated the comprehension level of all questions.
Furthermore, besides the experts’ review, the question-
naire’s validity was controlled using a ‘lie-catching’ item.
After collection of demographic data the question, ‘Have
you ever used CADs in your life? (yes/no)’ was useful for
ascertaining whether the patient had ever used CADs
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in general. The answer to this item had to report the
same construct of at least one of the two subsequent
questions, ‘Have you ever used CADs during the current
pregnancy? (yes/no)’ or ‘Have you ever used CADs in
a previous pregnancy or outside of pregnancy? (yes/no)’.
A positive answer, obtained at least once for these
two items, was coded as a dichotomous variable: the
combinations of answers ‘yes/yes’, ‘yes/no’, ‘no/yes’ were
coded with the same value which was different from ‘no/
no’; so this new variable could be compared, by means of
a 2 2 table with the response of the ‘lie-catching’ item.
Finally, to evaluate data reliability, 15 women, identi-
fied by means of an anonymous alphanumeric code, were
randomly selected for a test-to-retest investigation. The
questionnaire was administered twice, with an interval of
2 weeks between each interview. Closed-ended items with
more than one possible answer were not considered for
evaluation of agreement level.
Data Analysis
Categorical variables were expressed as percentage value
and analyzed with the Chi-square (2) test, while
continuous variables were reported as mean value
Standard Error of Mean (SEM) and analyzed using the
t-test or ANOVA. To check validity and reliability of
the questionnaire, evaluated by means of lie-catching and
test-to-retest, respectively, a K of Cohen was computed:
K-value, according to Landis and Koch was categorized
as fair (0.2–0.4), moderate (0.4–0.6), good (0.6–0.8) and
very good (0.8–1). Finally, to identify possible predictors
of CADs use, a multivariate logistic model was com-
puted. Variables included in the model were age, parity,
as well as participants’ characteristics that were possibly
found to be statistically different between the ‘user’ and
‘non-user’ groups.
A P-value <0.05 was considered statistically signifi-
cant. All analyses were performed using SPSS for
Windows, version 14.0 (Chicago Inc., Illinois, USA).
Results
Participants
A total of 172 women were consecutively contacted, with
a response rate of 87.2%. The mean age of the final
sample (150 women) was 32.4 0.4 years; most women
were nulliparae (62.7%) while 30, 5.3 and 2% were
primiparae, secondiparae and pluriparae, respectively.
With regard to their educational level, 72% of women
had a university degree. Nineteen (12.6%) participants
reported a chronic disease: diabetes (6 cases), asthma
(9 cases), hepatitis (2 cases) and blood coagulation
disorders (2 cases); 10 subjects reported concurrent use
of drugs: acetaminophen (2 cases), fraxiparine (2 cases),
aspirin (1 case), levotiroxine (3 cases) and corticosteroids
(2 cases).
The majority of subjects (68%) declared to have used at
least one CAD during their life while 48% reported
taking at least one of these products during current
pregnancy.
Questionnaire’s Validity and Reliability
Evaluation of validity revealed a very good agreement
(K=0.9; P<0.001) between dummy variable and the lie
catcher item ‘Have you ever used CADs in your life?
(yes/no)’. In fact only two women showed disagreeing
answers.
Consistently all K-values, computed by means of test-
to-retest evaluation, showed the questionnaire’s reproduc-
ibility exceeding 0.7 for every item.
Specifically the two key questions, ‘Have you used
CADs in a previous pregnancy or outside of pregnancy?
(yes/no)’ and ‘Have you ever used CADs during the
current pregnancy? (yes/no)’, reported a K of 0.9
(P<0.001) for both dichotomic answers.
Use of CADs Outside and/or in a Previous Pregnancy
The majority of women were nulliparae. In fact, only 10
women reported to have taken CADs during previous
pregnancies. For this reason, the analysis regarding
previous use of CADs was mainly based on pregnancy-
free periods. The characteristics of women, divided into
‘users’ or ‘non-users’ of CADs are reported in Table 1.
Table 1. Population characteristics of 150 Italian women according to
lifetime use (n=102) or non-use (n=48) of CADs
Lifetime usea
Variables Users Non-users P t 2
Age 32.4 1.0 32.5 0.8 0.901 (NS) 0.125 –
Weeks of amenorrhea 36.3 0.7 35.9 1.0 0.740 (NS) 0.333 –
Chronic diseaseb
Yes 14 (13.7) 5 (10.4) – – –
No 88 (86.3) 43 (89.6) 0.570 (NS) – 0.323
Level of education
Secondary or high
school
17 (23.6) 25 (32.1) – – –
University degree 55 (76.4) 53 (67.9) 0.250 (NS) 1.323
Parity
Nulliparae 68 (66.7) 26 (54.2) – – –
1 previous
pregnancies
34 (33.3) 22 (45.8) 0.140 (NS) – 2.180
Continuous variables (items) are expressed as mean value SEM;
categorical variables as absolute numbers and percentage values: n (%).
NS: not significant.
aRefers to the lie-catching item ‘Have you ever used CADs? (yes/no)’.
bDiabetes, asthma, hepatitis and blood coagulation disorders.
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2- and t-test did not show any difference among all
variables.
Use of CADs during the Current Pregnancy
The characteristics of participants, according to CADs
use during the current pregnancy, are presented in
Table 2. Previous use of CADs and concurrent use of
conventional drugs was significantly different between the
two groups. Women who were used to taking CADs, in
previous or out of pregnancy, reported a significantly
higher prevalence (84.7% versus 37.2%; P<0.001) of
CAD use also during the current pregnancy. Analogous
findings were present for women who were taking a
concurrent pharmacological therapy (13.9% versus 0%;
P=0.001). A logistic regression model including age,
previous CADs use, parity, confirmed these results:
women with previous CAD use showed a 10.8-fold
increased risk of taking CADs also during the current
pregnancy [adjusted Odds Ratio (OR)=10.8; 95%
confidence interval (CI): 4.7–25.0]. The other character-
istics included in the model did not significantly differ
between women using and not using CADs; the most
commonly used CADs are reported in Table 3. The
variable ‘concurrent pharmacological therapy’ was not
included in the model because one cell reported a null
value. Moreover, no significant difference was revealed
among numbers of CADs probably taken in different
periods of pregnancy (Table 4).
The percentage of women, who were not aware of the
type of CADs they were using, increased with the number
of products taken. Only 15.2% of subjects were able to
correctly classify all CADs that they were taking, while
Table 3. Prevalence of CADs use and reasons for use according to interview with women
CAD (classification)a N (%)b Main reason for use (number of cases/total)
Almond oil (herbal product) 20 (27.8) Prevent stretch marks (18/20)
Propolis (natural product) 14 (19.4) Sore throat (5/14)
Fennel (Foeniculum vulgare) and mauve
(Malva silvestris) tea (herbal product)
6 (8.3) Promote digestion (5/6)
Fennel (Foeniculum vulgare)
tea (herbal product)
5 (6.9) Swelling sensation (5/5)
Arnica (Arnica montana) (homeopathic
and herbal product)
3 (4.2) Hemorrhoids (1/3), contusion (1/3),
inflammation (1/3)
St John’s Wort (Hypericum perforatum)
oil (herbal product)
3 (4.2) Perineum relaxation (2/3)
Vegetable carbon (dietary supplement) 3 (4.2) Colitis (2/3)
Lemon balm (Melissa officinalis) and
chamomile (Chamaemelum nobile)
tea (herbal product)
3 (4.2) Anxiety (3/3)
Mauve (Malva silvestris) tea (herbal product) 3 (4.2) Inflammation (1/3), respiratory diseases,
not reported (1/3)
aClassification based on European Pharmacopeia (18).
bOnly the products with a prevalence of use for three women or more were included in the Table. Denominator is the number of users (n=72).
Table 2. Population characteristics of 150 Italian women according to
use (n=72) or non-use (n=78) of CADs during current pregnancy
Current pregnancy
Variables Users Non-users P t 2
Age 31.9 0.6 33.0 0.5 0.177 (NS) 1.357 –
Weeks of
amenorrhea
35.7 0.8 36.6 0.7 0.435 (NS) 0.783 –
Presence of chronic diseasea
Yes 9 (12.5) 10 (12.8) – – –
No 63 (87.5) 68 (87.2) 0.953 (NS) 0.003
Concurrent use of drugsb
Yes 10 (13.9) 0 – – –
No 62 (86.1) 78 (100) 0.001 – 11.067
Level of education
Secondary or
high school
17 (23.6) 25 (32.1) – – –
Degree 55 (76.4) 53 (67.9) 0.250 (NS) – 1.323
Previous use of CADsc
Yes 61 (84.7) 29 (37.2) – – –
No 11 (15.3) 49 (62.8) <0.001 – 35.261
Parity
Nullipara 44 (61.1) 50 (64.1) – – –
1 previous
pregnancies
28 (38.9) 28 (35.9) 0.705 (NS) – 0.143
Continuous variables (items) are expressed as mean value SEM;
categorical variables as absolute numbers and percentage values: n (%).
A p<0.05 value was considered statistically significant; NS: not
significant.
aDiabetes, asthma, hepatitis and blood coagulation disorders.
bAcetaminophen (2 cases), fraxiparine (2 cases), aspirin (1 case),
levothyroxine (3 cases), corticosteroids (2 cases).
cReferred to items ‘Have you used CADs in a previous pregnancy or
outside of pregnancy? (yes/no)’; previous use of CADs, during previous
pregnancies (n=10) or outside pregnancies (n=80).
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59.1% was not able to classify any of the products that
they were using (Table 5).
The mean numbers of CADs used during the three
pregnancy trimesters are reported in Table 5. No
significant differences in the correct classification of
CADs used were present among users in different
trimesters of pregnancy (Table 6).
Information Sources
As expected, the primary information source for the
majority of women during pregnancy were their gynecol-
ogist (32.6%) and midwife (19.5%) (Fig. 1). In contrast,
outside of pregnancy, they mainly relied upon herbalists
for information (50.4%) (Fig. 2).
Women’s Beliefs about CADs
The beliefs of participants about the safety and efficacy
of CADs are shown in Fig. 3 and 4. More than a half
(52%) of the sample were convinced that CADs are safer
than conventional medications during pregnancy, while
62.7% considered CADs as having equal efficacy as
conventional drugs.
Discussion
This is the first Italian study investigating attitudes,
beliefs and knowledge of CADs in pregnant women, and
is also the first work conducted with the aim at
characterizing CAD users. Although preliminary, these
results emphasize that the use of CADs during pregnancy
is a widespread habit among Italian women, who demo-
nstrate not to be able to classify the CADs in the proper
category. In fact 48% of the surveyed subjects used at
least one CAD during the current pregnancy and 59.1%
was not able to classify any of the products that they
were using.
The reliability and validity of the retrieved data are
high, as confirmed by the ‘very good’ level of agreement
reached by the test-to-retest analysis, as well as by means
of the lie-catchers comparison.
The prevalence of CAD use seems to be higher in Italy
than what is reported in studies performed in the USA
and in other European countries. Most research on drug
use in pregnancy reports between 3.6 and 15.9% CAD
use (including homeopathic and herbal drugs) (24,25).
Tsui et al. (26) conducted a survey among pregnant
Californians, in whom 13.3% reported using dietary
supplements. A paper of Nordeng et al. (27) investigated
the use of herbal drugs in 400 pregnant Norwegian
women reporting up to 36% use of herbal remedies. The
most recent and larger investigation reported that about
1 out of 1000 pregnant women (787 of 860 215 recorded
in the Swedish national birth register) had taken herbal
medications. Although this prevalence may seem low, it
should be noted that data were referred only to the first
trimester of pregnancy (16).
Also previous epidemiological studies conducted in
Italy mainly dealt only with the use of herbal remedies.
Zaffani et al. (17) conducted a research on 1044
randomly selected Italian women: 47.0% of the sample
reported using at least one herbal product, including
utilization in pregnancy or to treat their children’s
disease. Herbal products were mainly taken in combina-
tion with conventional drugs or homeopathic remedies.
The prevalence of CAD use during pregnancy reported
in the present study (48.0%) is consistent with what is
reported by Zaffani et al. (17). Nevertheless, in our
sample, no significant difference was present in socio-
demographic variables between CAD users and non-
users, whereas Zaffani et al. reported a higher use among
highly educated women, aged 31–40 years and employed,
confirming previous results of studies performed in Italy
(6) as well as in other countries (2,4). However, it is
worth mentioning that these studies were focused on
phytotherapy, while the present research was aimed at
Table 5. Percentage of CADs wronglya classified by the participants
Wrong CADs
classification (%)
N (%)
0 10 (15.2)
50 11 (16.7)
66 2 (3.0)
75 1 (1.5)
80 1 (1.5)
83 1 (1.5)
88 1 (1.5)
100 39 (59.1)
Totalb 66 (100)
aComparison was performed by means of European Pharmacopoeia (18).
b6/72 (8.3%) subjects were not able to remember the type of product
used, its classification or both.
Table 4. Analysis of variance (ANOVA) among mean number (SEM) of CADs by trimester patterns of use
Trimester
1st 2nd 3rd 1st and 3rd 2nd and 3rd 1st, 2nd and 3rd F P
2.0 0.4 1.6 0.2 1.9 0.3 2.0 0.0 2.1 0.4 2.6 0.9 0.516 0.763 (NS)
NS: not significant.
SEM: Standard Error of Mean.
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exploring the use of any so-called ‘products manufac-
tured from herbs and/or with a natural origin’. So these
socio-demographic features may therefore pertain to
subjects seeking a phytotherapeutic approach, while the
use of CADs appears, in general, to be less restricted to
social classes.
The two most important variables with predictor
meaning were identified as (i) current use of conventional
drugs and (ii) habitual use of CADs (other than in
current pregnancy). The first one has been reported only
in univariate analysis because one cell revealed a null
value. The latter one is the most interesting factor:
adjusted OR revealed a 10.8-fold increase concerning the
risk of CAD use in pregnancy if the woman was a
habitual user of this kind of therapy.
The importance of identifying risk factors for CAD use
in pregnancy underlies the possible maternal and foetal
damage of some non-conventional medications. For
instance, recent research (28,29) showed the possible
teratogenic effect of several Chinese herbal medicines
when used during pregnancy. Holst and coworkers (16)
reported no signs of unfavorable effect of herbal drug use
on pregnancy outcome; nevertheless, they did not exclude
possible rare adverse effects such as foetal malformations.
For example, the safety profile of Ginseng, Valerian, St.
John’s Wort, Gingko, Propolis, Chamomile is not clearly
defined and, for some of them, their use in pregnancy is
contraindicated because of the potential harm for the
mother and/or foetus as well as the potential adverse
effect affecting childbirth (8–14).
Figure 3. Pregnant women’s opinions about efficacy of CADs when
compared with traditional medications (n=150).
Figure 4. Pregnant women’s opinions about safety of CADs when
compared with traditional medications (n=150).
Table 6. Analysis of variance (ANOVA) among mean percentages (SEM) of correctly classified CADs, by trimester patterns of use
Trimester
1st 2 nd 3 rd 1st and 3rd 2nd and 3rd 1st, 2nd and 3rd F P
61.8 14.8 74.3 10.6 76.4 8.4 66.6 16.6 72.5 13.1 79.8 8.8 0.283 0.920 (NS)
NS: not significant.
SEM: Standard Error of Mean.
Figure 1. Information sources on CADs during current pregnancy
(n=150).
Figure 2. Information sources on CADs in previous pregnancy or
outside of pregnancy (n=150).
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In this context it is worth mentioning the recent paper
of Tournaire et al. (30) discussing the role of comple-
mentary and alternative therapies in reducing pain during
delivery. Many CAM remedies could be used in this
context, but healthcare providers are still unready to
apply a correct evidence-based approach because of their
poor knowledge and the scanty data availability. Also for
these reasons, the possibility of identifying CADs users
before attempting a pregnancy, might be very useful also
for the application of non-conventional therapies to
facilitate the delivery.
Additionally, a feature that was not previously assessed
in other research is the knowledge that women have
about the nature of assumed CADs. A high level of
wrong classification of CADs could expose women and/
or the foetus to additional risks. Since the CAM area
includes different heterogeneous aspects and disciplines, it
is not surprising that users may be mislead when asked to
classify CADs. The clinical consequences of this problem
could result in an evident risk of using, for example, an
herbal drug or a natural product with the conviction of
taking a homeopathic drug. In the present study,
propolis, the second most used product in this survey,
was always wrongly considered a homeopathic remedy.
This is quite relevant because, although its efficacy still
remains controversial (28), the safety of propolis is widely
questioned. This natural product is not devoid of adverse
effects, some of which are extremely severe such as
anaphylactic shock (31). Consistenly, St. John’s Wort and
chamomile, assumed by 4.2% of the participants, are not
supported by an adequate information on their safety
profile in pregnancy, and women could use these
preparations without knowing their actual formulation
(8–14). On this purpose a fatal case report of anaphylaxis
due to chamomile tea during pregnancy has been
reported (32).
The increased risk of taking CADs during the first and
second trimester of pregnancy (higher teratogenic risk)
was also unknown to most of the women in the study.
The prevalence of CAD use was similar during the three
trimesters and the percent of wrong classification of
CADs was also the same. Consistently, pregnant women
seem to be confident with CADs and more than half of
them considered CADs safer than conventional medi-
cines. A positive note emerging from these data is that
pregnant women refer primarily to gynecologists and
midwives as their principal source of information for
CAD use during pregnancy. However, only 32.6% of
participants consulted a healthcare professional from the
obstetrics field, confirming the risk that CADs could be
used without an accurate clinical control. This is quite
similar to what happens outside pregnancy; in fact, more
than 60% of subjects, using alternative treatments, do
not report the use to their doctor (4).
Yet, out of pregnancy, participants seem commonly to
consult an herbalist to receive advice on CADs. In other
studies pregnant women referred to herbal stores and
pharmacies or generally used herbal drugs on their own
initiative (33,17). This kind of behavior could have
important clinical consequences, especially in Italy and
in other countries where herbalists are not professional
healthcare givers, and their suggestions in terms of
efficacy and safety of CADs, both to pregnant and
non-pregnant women, could be misleading.
Limitations
A limitation of this survey was reliance on a non-random
sampling procedure for the questionnaire phase. This
issue, together with the small sample enrolled, may affect
the transferability of our findings to the whole popula-
tion. Moreover the items that investigated the previous
use of CADs could be affected by recall bias. Finally, the
higher prevalence of well-educated women (72% reported
a university degree) might have influenced the analysis in
terms of the participants’ capability of classifying CADs.
Conclusions
This preliminary study confirms the need of exploring the
attitudes, beliefs and knowledge of CADs among Italian
pregnant women. In light of the validity and reliability of
the questionnaire, these results suggest the necessity of
developing counselling strategies focusing on CAD use
during pregnancy, especially for habitual users. Since in
Italy, as in many other Western countries, standardized
scientific testing of CADs is not required by regulatory
agencies before marketing, their use in pregnancy should
always be under the guidance of an expert physician. In
this context, an effective information campaign concern-
ing these products appears fundamental for pregnant
Italian women, who seem to consider a product labeled
‘natural’ as being synonymous with ‘safe’.
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